Avirmax Biopharma, Inc. based in San Francisco Bay Area, is a preclinical stage biopharmaceutical company focusing on innovation and development of genetic medicines to treat chronic and degenerated ocular diseases using integrated solutions in engineering and optimization of adeno-associated virus (AAV) vectors, rich experience and knowledge in biopharmaceutical development and product supply. Our mission is to deliver patients with safe, effective, durable, affordable and accessible AAV-mediated biotherapeutics to preserve patient’s vision.